ReviewWorld journal of gastroenterology2021
Interaction between hepatitis B virus and SARS-CoV-2 infections.
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Hepatitis B associated with severe COVID-19: a nationwide cohort study in Sweden.Virology journal · 2025Article
- Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China.Liver research (Beijing, China) · 2025Article
- Hepatitis B virus associated with severe acute respiratory syndrome coronavirus 2 infection: a case report.Journal of medical case reports · 2025Article
- Observational
- Effect of SARS-CoV-2 infection on liver function in patients with hepatitis B.BMC infectious diseases · 2024Article
- Impacts of optimal control strategies on the HBV and COVID-19 co-epidemic spreading dynamics.Scientific reports · 2024Article
- Article
- Association of current hepatitis B virus infection with mortality in adults with sepsis.Epidemiology and infection · 2023Article
- T Cell Response to SARS-CoV-2 Coinfection and Comorbidities.Pathogens (Basel, Switzerland) · 2023Review
- Review
- COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023Review
- Analysis of HBV and COVID-19 Coinfection Model with Intervention Strategies.Computational and mathematical methods in medicine · 2023Article
- Liver injury in COVID-19: A minireview.World journal of gastroenterology · 2022Review
- Viral Coinfections.Viruses · 2022Review
- Patients with COVID-19 and HBV Coinfection are at Risk of Poor Prognosis.Infectious diseases and therapy · 2022Article
- Presumed Protective Role for Anti-Hepatitis B Virus Antibodies Against COVID-19 Severe Cases: A Clinical Study ConfirmingFrontiers in medicine · 2022Article
- A systems biology approach for investigating significantly expressed genes among COVID-19, hepatocellular carcinoma, and chronic hepatitis B.The Egyptian journal of medical human genetics · 2022Article
- Letter to the Editor: Unanswered questions about hepatitis B virus infection in patients with COVID-19.Hepatology (Baltimore, Md.) · 2022Article
- Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) /Hepatitis B virus (HBV) Co-infected Patients: A case series and review of the literature.International journal of clinical practice · 2021Review
- Viral coinfections in COVID-19.Journal of medical virology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) has become a global pandemic and garnered international attention. The causative pathogen of COVID-19 is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel, highly contagious coronavirus. Numerous studies have reported that liver injury is quite common in patients with COVID-19. Hepatitis B has a worldwide distribution as well as in China. At present, hepatitis B virus (HBV) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma. Because both viruses challenge liver physiology, it raises questions as to how coinfection with HBV and SARS-CoV-2 affect disease progression and mortality. Is there an increased risk of COVID-19 in patients with HBV infection? In this review, we summarize the current reports of SARS-CoV-2 and HBV coinfection and elaborate the interaction of the two diseases. The emphasis was placed on evaluating the impact of HBV infection on disease severity and clinical outcomes in patients with COVID-19 and discussing the potential mechanism behind this effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.